Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT
Jefferies began covering Biogen Inc. (NASDAQ:BIIB) on September 26 with a Buy rating and a price target of $190.
Biogen Inc. (BIIB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 3,831,727 | $481,226,574 | +841% | 0.94% |
| 2. | D E Shaw D. E. Shaw | 1,366,207 | $171,581,937 | -14% | 0.12% |
| 3. | AQR Capital Management Cliff Asness | 1,364,805 | $171,405,897 | -1% | 0.14% |
| 4. | Renaissance Technologies Jim Simons | 1,045,106 | $131,254,863 | +30% | 0.17% |
| 5. | Balyasny Asset Management Dmitry Balyasny | 831,905 | $104,478,949 | +6% | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $122.72 | 1,235 | $151,559.20 | 27,842 | 2025-05-02 | Filing | |
| $222.54 | 455 | $101,255.70 | 20,629 | 2024-02-15 | Filing | |
| $267.00 | 898 | $239,766.00 | 2,943 | 2021-02-09 | Filing | |
| $241.31 | 3,100 | $748,046.74 | 34,810 | 2020-11-30 | Filing | |
| $231.24 | 38,000 | $8,787,120.00 | 643,000 | 2019-05-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $133.55 | 517 | $69,045.35 | 5,772 | 2025-09-02 | Filing | |
| $135.00 | 2,223 | $300,105.00 | 6,330 | 2025-07-08 | Filing | |
| $126.25 | 3,806 | $480,507.50 | 5,427 | 2025-05-19 | Filing | |
| $150.02 | 8,760 | $1,314,141.91 | 11,318 | 2025-03-07 | Filing | |
| $157.21 | 110 | $17,293.10 | 5,426 | 2024-12-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,451,249 | $203,290,960 | 0.51% | |
| 2. | 232,439 | $32,560,055 | 0.03% | |
| 3. | 192,872 | $27,017,510 | 0.46% | |
| 4. | 63,289 | $8,865,523 | 0.01% | |
| 5. | 38,755 | $5,428,801 | 0.41% |
News See All
12 Best Widow and Orphan Stocks to Buy According to Analysts
According to Reuters, U.S. stock index futures increased on September 29.
Biogen Inc. (BIIB): A Bull Case Theory
We came across a bullish thesis on Biogen Inc. on Investing With Purpose’s Substack. In this article, we will summarize the bulls’ thesis on BIIB.
Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued
Biogen Inc. (NASDAQ:BIIB) ranks among the most undervalued NASDAQ stocks to buy now. On September 18, Biogen Inc.
14 Most Undervalued NASDAQ Stocks to Buy Now
On September 22, stocks surged to mark a third consecutive day of record-high closes, driven by hopes that the AI trade and additional Fed policy easing would boost the upward trend.
Canaccord Genuity Reiterates a Buy on Biogen (BIIB)
Biogen Inc. (NASDAQ:BIIB) is one of the best drug stocks to buy right now. In a report released on September 12, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biogen Inc.
H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects
Biogen Inc. (NASDAQ:BIIB) is one of the best defensive stocks to buy, according to Steve Cohen. On September 5, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $194 price target.
12 Best Drug Stocks to Buy Right Now
Dr. Marty stated that these ads are, by regulation, supposed to create a fair balance of information.
10 Best Defensive Stocks to Buy According to Steve Cohen
Is it time to rebalance investment portfolios on equity valuations soaring with the S&P 500 powering through the 6,500 level? That’s the big question as uncertainty in the US economy hits hard amid ...
Hedge Fund Resource Center Billionaire Hedge Funds
